On this page
How do you write a REMS assessment report that supports a defensible conclusion?
Use the operative REMS versions, assessment plan, reporting interval and actual data cutoff. Report each metric with its population, definitions, method, result and limitations, then assess each goal separately. Explain missing evidence and proposed next actions instead of converting incomplete data into success. The 2019 FDA assessment guidance remains draft; the approved program and applicable agency instructions establish the actual reporting baseline.
Before you begin
Assessment reporting for an actual REMS. Use the approved REMS, assessment timetable, agreed plan and agency correspondence as the operative baseline. FDA’s 2019 assessment guidance remains draft.
What you will prepare: An assessment report linking each required or agreed question to its method, result, limitation and proposed action.
Identify the period and program actually assessed
Collect the operative REMS versions, timetable, assessment plan, instruments, prior assessments and correspondence. Specify reporting period and data cutoff. If the program changed during the interval, identify which requirements and materials were in effect when. The 2019 draft suggests a report organization; it does not replace the product’s approved requirements or establish a universal deadline.
Report every assessment question transparently
Organize results by the actual plan. For each metric, identify the source, population, numerator/denominator where relevant, method, missingness and result. Distinguish process completion from meaningful risk mitigation. If a metric cannot be calculated, explain why, the impact on interpretation and the proposed remedy. Do not substitute a convenient available measure and report the original question as answered.
Explain what the evidence can and cannot establish
Compare findings with the relevant objective and prior period using compatible definitions. Identify operational changes, survey selection, incomplete follow-up or other limitations. A high training-completion rate does not automatically prove correct clinical behavior. Proposals to change or eliminate an element require a reasoned case and the appropriate separate process; a favorable report does not itself modify the REMS.
Fictional example: the denominator changed
A dashboard shows improvement, but the prior report counted all eligible participants while this report counts only respondents. Recalculate on a justified comparable basis or explain why a trend cannot be inferred. If the protocol version cannot be found, recover it before claiming the prespecified analysis was followed. Keep an unresolved result visible rather than turning missing data into a passing assessment.
Make each conclusion traceable to a defined result
Build a result record for every question in the actual assessment plan before writing the executive summary. Preserve measures that were not calculable or not collected; deleting them makes a partial assessment look complete.
| Result field | Report | Check before interpretation |
|---|---|---|
| Program and period | Requirement/material versions, interval and cutoff | Did the program change during the period? |
| Metric definition | Exact question, population and unit of analysis | Are people, encounters and transactions being mixed? |
| Data and method | Source, instrument, protocol and analysis version | What changed from the planned method? |
| Observed result | Numerator, denominator, uncertainty and missingness as applicable | Can the reported value be reconciled to the actual records? |
| Comparison | Prespecified criterion or compatible prior-period result | Are the compared populations and definitions the same? |
| Interpretation | What the finding supports and what remains uncertain | Does a process measure justify the claimed outcome? |
| Next action | Supported proposal, evidence needed and owner | Does implementation require a separate change process? |
Fictional missing-data exercise: 1,000 participants were eligible for a knowledge survey, 200 responded and 180 respondents answered a key question correctly. The observed result is 90% among respondents, with a 20% response rate. It does not establish 90% knowledge among all eligible participants. Conversely, 180 divided by 1,000 is not a measured 18% knowledge rate, because the other answers are unknown. Assess nonresponse and the planned analysis, and report the limitation explicitly.
Reconcile period-specific and cumulative numbers using their definitions. Do not add cumulative counts across reports and count the same participants repeatedly. When the program, eligibility rule or instrument changes, show the break in comparability and provide an appropriate stratified or otherwise justified analysis. Explain why a trend is interpretable before describing it as improvement.
The January 2019 draft recommends discussing results for individual goals and the program overall. A program can have evidence that one objective is being met while another is unresolved or not met. Avoid a single favorable headline that hides the distinction. Where evidence is insufficient, identify the additional data or analysis that could resolve the question.
For REMS with elements to assure safe use, the draft also discusses patient access and burden on the health-care system. Consider evidence about delays, abandonment, workflow difficulty and participant experience where relevant to the actual plan. Low use alone does not prove the REMS caused an access problem; investigate alternative explanations and the limitations of each source.
Use the methodology guide to describe what was planned and departures from it. Use the change-history guide for proposed modifications. An assessment recommendation to remove an element is not itself authority to stop performing an approved requirement.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does a high training-completion rate establish that the REMS reduced the clinical risk?
Not by itself. Training completion measures a process, while knowledge, safe-use behavior and clinical outcomes concern different questions. Explain how the selected evidence relates to the actual goal and preserve limitations. Do not turn a completed activity into a demonstrated risk-reduction effect without appropriate supporting evidence.
How should nonrespondents be handled in a REMS knowledge-survey report?
Report the response rate, relevant sampling information and the planned handling of missing responses. A respondent-only knowledge percentage does not automatically describe all eligible participants, and nonresponse should not silently be coded as either correct or incorrect. Explain the resulting limitations and any justified analyses.
Can a favorable assessment report remove a REMS requirement?
The report can support a proposed change but does not itself modify the operative REMS. Establish the appropriate change process and actual decision before treating a requirement as removed. Preserve the assessment evidence, rationale and affected-document relationships so the proposal can be reviewed on its merits.
Must all REMS goals receive the same overall success conclusion?
No. Assess each goal or objective using the relevant evidence, then explain the overall conclusion. The draft guidance explicitly discusses partially met goals and evidence insufficient to determine a result. A favorable finding for one measure should not conceal a failed, missing or inconclusive assessment elsewhere.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
FDA: Format and Content of a REMS Document ↗January 2023 final guidance; III.A–F and IV. Distinguishes REMS document, materials and supporting document. Checked September 22, 2026.
Draft guidance
FDA draft: REMS Assessment: Planning and Reporting ↗January 2019 PDF cover; February 2019 FDA landing page. Still draft/not for implementation when checked September 22, 2026. III–VI provide proposed assessment organization, not a replacement for the approved REMS.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.16.2.3. A heading identifies placement, not mandatory applicability.

